{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T14:59:01Z","timestamp":1770562741774,"version":"3.49.0"},"reference-count":82,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cooperative agreement between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of the Army","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>The immense global diversity of HIV-1 is a significant obstacle to developing a safe and effective vaccine. We recently showed that infections established with multiple founder variants are associated with the development of neutralization breadth years later. We propose a novel vaccine design strategy that integrates the variability observed in acute HIV-1 infections with multiple founder variants. We developed a probabilistic model to simulate this variability, yielding a set of sequences that present the minimal diversity seen in an infection with multiple founders. We applied this model to a subtype C consensus sequence for the Envelope (Env) (used as input) and showed that the simulated Env sequences mimic the mutational landscape of an infection with multiple founder variants, including diversity at antibody epitopes. The derived set of multi-founder-variant-like, minimally distant antigens is designed to be used as a vaccine cocktail specific to a HIV-1 subtype or circulating recombinant form and is expected to promote the development of broadly neutralizing antibodies.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1010624","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T17:37:38Z","timestamp":1667237858000},"page":"e1010624","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimal sequence-based design for multi-antigen HIV-1 vaccines using minimally distant antigens"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6459-2437","authenticated-orcid":true,"given":"Eric","family":"Lewitus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7038-2671","authenticated-orcid":true,"given":"Yifan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3501-3974","authenticated-orcid":true,"given":"Hongjun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3650-8490","authenticated-orcid":true,"given":"Morgane","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"issue":"4882","key":"pcbi.1010624.ref001","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.2460925","article-title":"The accuracy of reverse transcriptase from HIV-1","volume":"242","author":"JD Roberts","year":"1988","journal-title":"Science"},{"issue":"2","key":"pcbi.1010624.ref002","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.virusres.2012.06.015","article-title":"The origin of genetic diversity in HIV-1","volume":"169","author":"RP Smyth","year":"2012","journal-title":"Virus Res"},{"issue":"9","key":"pcbi.1010624.ref003","doi-asserted-by":"crossref","first-page":"e1002251","DOI":"10.1371\/journal.pbio.1002251","article-title":"Extremely High Mutation Rate of HIV-1 In Vivo.","volume":"13","author":"JM Cuevas","year":"2015","journal-title":"PLoS Biol"},{"issue":"7","key":"pcbi.1010624.ref004","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"DD Richman","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6929","key":"pcbi.1010624.ref005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"X Wei","year":"2003","journal-title":"Nature"},{"issue":"24","key":"pcbi.1010624.ref006","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.","volume":"82","author":"GD Tomaras","year":"2008","journal-title":"J Virol"},{"issue":"1","key":"pcbi.1010624.ref007","doi-asserted-by":"crossref","first-page":"e1001251","DOI":"10.1371\/journal.ppat.1001251","article-title":"Characteristics of the earliest cross-neutralizing antibody response to HIV-1.","volume":"7","author":"I Mikell","year":"2011","journal-title":"PLoS Pathog."},{"issue":"10","key":"pcbi.1010624.ref008","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1128\/JVI.00198-11","article-title":"The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.","volume":"85","author":"ES Gray","year":"2011","journal-title":"J Virol"},{"issue":"14","key":"pcbi.1010624.ref009","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.","volume":"83","author":"MD Simek","year":"2009","journal-title":"J Virol"},{"issue":"2","key":"pcbi.1010624.ref010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.","volume":"28","author":"P Hraber","year":"2014","journal-title":"AIDS"},{"issue":"2","key":"pcbi.1010624.ref011","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/JVI.02036-08","article-title":"Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.","volume":"83","author":"DN Sather","year":"2009","journal-title":"J Virol"},{"issue":"19","key":"pcbi.1010624.ref012","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1128\/JVI.01149-09","article-title":"Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.","volume":"83","author":"A Piantadosi","year":"2009","journal-title":"J Virol"},{"issue":"11","key":"pcbi.1010624.ref013","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/nm.2985","article-title":"Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.","volume":"18","author":"PL Moore","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"pcbi.1010624.ref014","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","article-title":"Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.","volume":"153","author":"F Klein","year":"2013","journal-title":"Cell"},{"issue":"10","key":"pcbi.1010624.ref015","doi-asserted-by":"crossref","first-page":"e1003738","DOI":"10.1371\/journal.ppat.1003738","article-title":"Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.","volume":"9","author":"CK Wibmer","year":"2013","journal-title":"PLoS Pathog.PubMed Central PMCID"},{"issue":"22","key":"pcbi.1010624.ref016","doi-asserted-by":"crossref","first-page":"12968","DOI":"10.1128\/JVI.01816-14","article-title":"Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.","volume":"88","author":"DN Sather","year":"2014","journal-title":"J Virol"},{"issue":"3","key":"pcbi.1010624.ref017","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2014.06.022","article-title":"Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.","volume":"158","author":"F Gao","year":"2014","journal-title":"Cell"},{"issue":"1","key":"pcbi.1010624.ref018","doi-asserted-by":"crossref","first-page":"e1005369","DOI":"10.1371\/journal.ppat.1005369","article-title":"Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.","volume":"12","author":"E Landais","year":"2016","journal-title":"PLoS Pathog."},{"issue":"11","key":"pcbi.1010624.ref019","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/nm.4187","article-title":"Determinants of HIV-1 broadly neutralizing antibody induction.","volume":"22","author":"P Rusert","year":"2016","journal-title":"Nat Med"},{"issue":"7723","key":"pcbi.1010624.ref020","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41586-018-0517-0","article-title":"Tracing HIV-1 strains that imprint broadly neutralizing antibody responses","volume":"561","author":"RD Kouyos","year":"2018","journal-title":"Nature"},{"issue":"37","key":"pcbi.1010624.ref021","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1073\/pnas.1505207112","article-title":"Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising.","volume":"112","author":"S Luo","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"pcbi.1010624.ref022","doi-asserted-by":"crossref","first-page":"9415","DOI":"10.1128\/JVI.02732-09","article-title":"Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.","volume":"84","author":"RL Powell","year":"2010","journal-title":"J Virol"},{"issue":"3","key":"pcbi.1010624.ref023","doi-asserted-by":"crossref","first-page":"e1002611","DOI":"10.1371\/journal.ppat.1002611","article-title":"HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response.","volume":"8","author":"V Cortez","year":"2012","journal-title":"PLoS Pathog.PubMed Central PMCID"},{"issue":"4","key":"pcbi.1010624.ref024","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.chom.2018.09.001","article-title":"HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth.","volume":"24","author":"DJ Sheward","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"2","key":"pcbi.1010624.ref025","doi-asserted-by":"crossref","first-page":"e1008179","DOI":"10.1371\/journal.ppat.1008179","article-title":"Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand.","volume":"16","author":"M Rolland","year":"2020","journal-title":"PLoS Pathog."},{"issue":"2","key":"pcbi.1010624.ref026","doi-asserted-by":"crossref","first-page":"e1008537","DOI":"10.1371\/journal.pcbi.1008537","article-title":"Factors influencing estimates of HIV-1 infection timing using BEAST.","volume":"17","author":"B Dearlove","year":"2021","journal-title":"PLoS Comput Biol"},{"issue":"3","key":"pcbi.1010624.ref027","doi-asserted-by":"crossref","first-page":"e1010369","DOI":"10.1371\/journal.ppat.1010369","article-title":"HIV-1 infections with multiple founders associate with the development of neutralization breadth","volume":"18","author":"E Lewitus","year":"2022","journal-title":"PLoS Pathog"},{"key":"pcbi.1010624.ref028","article-title":"B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies.","author":"SM Townsley","year":"2021","journal-title":"Cell Host Microbe."},{"issue":"22","key":"pcbi.1010624.ref029","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1056\/NEJMoa1508952","article-title":"Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand","volume":"374","author":"ML Robb","year":"2016","journal-title":"N Engl J Med"},{"key":"pcbi.1010624.ref030","article-title":"Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.","author":"M Rolland","year":"2012","journal-title":"Nature"},{"issue":"2","key":"pcbi.1010624.ref031","doi-asserted-by":"crossref","first-page":"veab057","DOI":"10.1093\/ve\/veab057","article-title":"RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection.","volume":"7","author":"E Lewitus","year":"2021","journal-title":"Virus Evol."},{"issue":"7","key":"pcbi.1010624.ref032","doi-asserted-by":"crossref","first-page":"100315","DOI":"10.1016\/j.xcrm.2021.100315","article-title":"Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection in fetuses","volume":"2","author":"MH Marichannegowda","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"pcbi.1010624.ref033","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1038\/s41467-020-18225-x","article-title":"Broadly neutralizing plasma antibodies effective against autologous circulating viruses in infants with multivariant HIV-1 infection.","volume":"11","author":"N Mishra","year":"2020","journal-title":"Nat Commun."},{"issue":"21","key":"pcbi.1010624.ref034","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"BF Keele","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"pcbi.1010624.ref035","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/JVI.02132-08","article-title":"Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants","volume":"83","author":"MR Abrahams","year":"2009","journal-title":"J Virol"},{"issue":"10","key":"pcbi.1010624.ref036","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/nm.3932","article-title":"HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders","volume":"21","author":"H Janes","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"pcbi.1010624.ref037","doi-asserted-by":"crossref","first-page":"e1005619","DOI":"10.1371\/journal.ppat.1005619","article-title":"Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus.","volume":"12","author":"DC Tully","year":"2016","journal-title":"PLoS Pathog."},{"issue":"11","key":"pcbi.1010624.ref038","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.","volume":"384","author":"L Corey","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"pcbi.1010624.ref039","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/molbev\/msn067","article-title":"An improved general amino acid replacement matrix","volume":"25","author":"SQ Le","year":"2008","journal-title":"Mol Biol Evol"},{"issue":"3","key":"pcbi.1010624.ref040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/sysbio\/syv116","article-title":"Characterizing and Comparing Phylogenies from their Laplacian Spectrum","volume":"65","author":"E Lewitus","year":"2016","journal-title":"Syst Biol"},{"issue":"2","key":"pcbi.1010624.ref041","doi-asserted-by":"crossref","first-page":"vez044","DOI":"10.1093\/ve\/vez044","article-title":"A non-parametric analytic framework for within-host viral phylogenies and a test for HIV-1 founder multiplicity.","volume":"5","author":"E Lewitus","year":"2019","journal-title":"Virus Evol."},{"issue":"5993","key":"pcbi.1010624.ref042","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"X Wu","year":"2010","journal-title":"Science"},{"issue":"1","key":"pcbi.1010624.ref043","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency","volume":"90","author":"NA Doria-Rose","year":"2016","journal-title":"J Virol"},{"issue":"5","key":"pcbi.1010624.ref044","doi-asserted-by":"crossref","first-page":"e1003342","DOI":"10.1371\/journal.ppat.1003342","article-title":"Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.","volume":"9","author":"JP Julien","year":"2013","journal-title":"PLoS Pathog."},{"issue":"6","key":"pcbi.1010624.ref045","doi-asserted-by":"crossref","first-page":"e0157409","DOI":"10.1371\/journal.pone.0157409","article-title":"Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.","volume":"11","author":"C Soto","year":"2016","journal-title":"PLoS One."},{"issue":"7525","key":"pcbi.1010624.ref046","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature13601","article-title":"Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface","volume":"515","author":"J Huang","year":"2014","journal-title":"Nature"},{"issue":"7873","key":"pcbi.1010624.ref047","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"J Jumper","year":"2021","journal-title":"Nature"},{"issue":"12","key":"pcbi.1010624.ref048","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.","volume":"194","author":"P Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"issue":"5","key":"pcbi.1010624.ref049","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.","volume":"191","author":"NM Flynn","year":"2005","journal-title":"J Infect Dis"},{"issue":"9653","key":"pcbi.1010624.ref050","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet."},{"issue":"23","key":"pcbi.1010624.ref051","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"pcbi.1010624.ref052","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.","volume":"11","author":"GE Gray","year":"2011","journal-title":"Lancet Infect Dis."},{"issue":"22","key":"pcbi.1010624.ref053","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine.","volume":"369","author":"SM Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"pcbi.1010624.ref054","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.","volume":"384","author":"GE Gray","year":"2021","journal-title":"N Engl J Med"},{"issue":"228","key":"pcbi.1010624.ref055","doi-asserted-by":"crossref","first-page":"228ra38","DOI":"10.1126\/scitranslmed.3007736","article-title":"Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.","volume":"6","author":"AW Chung","year":"2014","journal-title":"Sci Transl Med."},{"issue":"12","key":"pcbi.1010624.ref056","doi-asserted-by":"crossref","first-page":"e1009101","DOI":"10.1371\/journal.ppat.1009101","article-title":"RV144 HIV-1 vaccination impacts post-infection antibody responses.","volume":"16","author":"T Mdluli","year":"2020","journal-title":"PLoS Pathog.PubMed Central PMCID"},{"issue":"5","key":"pcbi.1010624.ref057","doi-asserted-by":"crossref","first-page":"e0126742","DOI":"10.1371\/journal.pone.0126742","article-title":"Computational Identification of Antigenicity-Associated Sites in the Hemagglutinin Protein of A\/H1N1 Seasonal Influenza Virus.","volume":"10","author":"X Ren","year":"2015","journal-title":"PLoS One."},{"issue":"4","key":"pcbi.1010624.ref058","doi-asserted-by":"crossref","first-page":"e1002492","DOI":"10.1371\/journal.pcbi.1002492","article-title":"Inference of genotype-phenotype relationships in the antigenic evolution of human influenza A (H3N2) viruses.","volume":"8","author":"L Steinbruck","year":"2012","journal-title":"PLoS Comput Biol."},{"issue":"12","key":"pcbi.1010624.ref059","doi-asserted-by":"crossref","first-page":"E1701","DOI":"10.1073\/pnas.1525578113","article-title":"Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses","volume":"113","author":"RA Neher","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pcbi.1010624.ref060","doi-asserted-by":"crossref","first-page":"vev025","DOI":"10.1093\/ve\/vev025","article-title":"Determination of antigenicity-altering patches on the major surface protein of human influenza A\/H3N2 viruses.","volume":"2","author":"C Kratsch","year":"2016","journal-title":"Virus Evol."},{"issue":"7490","key":"pcbi.1010624.ref061","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature13087","article-title":"A predictive fitness model for influenza.","volume":"507","author":"M Luksza","year":"2014","journal-title":"Nature"},{"key":"pcbi.1010624.ref062","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/bmb\/58.1.19","article-title":"Evolutionary and immunological implications of contemporary HIV-1 variation","volume":"58","author":"B Korber","year":"2001","journal-title":"Br Med Bull"},{"issue":"5577","key":"pcbi.1010624.ref063","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1126\/science.1070441","article-title":"Diversity considerations in HIV-1 vaccine selection","volume":"296","author":"B Gaschen","year":"2002","journal-title":"Science"},{"issue":"3","key":"pcbi.1010624.ref064","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/COH.0000000000000545","article-title":"HIV-1 phylogenetics and vaccines","volume":"14","author":"M. Rolland","year":"2019","journal-title":"Curr Opin HIV AIDS"},{"issue":"38","key":"pcbi.1010624.ref065","doi-asserted-by":"crossref","first-page":"23652","DOI":"10.1073\/pnas.2008281117","article-title":"A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants","volume":"117","author":"B Dearlove","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"pcbi.1010624.ref066","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1128\/JVI.02683-06","article-title":"Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins","volume":"81","author":"M Rolland","year":"2007","journal-title":"J Virol"},{"issue":"1","key":"pcbi.1010624.ref067","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"W Fischer","year":"2007","journal-title":"Nat Med"},{"issue":"3","key":"pcbi.1010624.ref068","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.2089","article-title":"Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys","volume":"16","author":"O Barouch DH","year":"2010","journal-title":"Nat Med"},{"issue":"10143","key":"pcbi.1010624.ref069","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13\u201319).","volume":"392","author":"DH Barouch","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"pcbi.1010624.ref070","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1371\/journal.pone.0000984","article-title":"Design and pre-clinical evaluation of a universal HIV-1 vaccine","volume":"2","author":"S Letourneau","year":"2007","journal-title":"PLoS One"},{"issue":"11","key":"pcbi.1010624.ref071","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1371\/journal.ppat.0030157","article-title":"HIV-1 group M conserved elements vaccine","volume":"3","author":"M Rolland","year":"2007","journal-title":"PLoS Pathog"},{"issue":"6439","key":"pcbi.1010624.ref072","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1126\/science.aav5095","article-title":"Structural topology defines protective CD8(+) T cell epitopes in the HIV proteome.","volume":"364","author":"GD Gaiha","year":"2019","journal-title":"Science"},{"issue":"3","key":"pcbi.1010624.ref073","article-title":"Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth.","volume":"8","author":"N Moyo","year":"2020","journal-title":"Vaccines (Basel)."},{"issue":"6133","key":"pcbi.1010624.ref074","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"J Jardine","year":"2013","journal-title":"Science"},{"issue":"4","key":"pcbi.1010624.ref075","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/bioinformatics\/16.4.400","article-title":"Detecting hypermutations in viral sequences with an emphasis on G\u2014> A hypermutation","volume":"16","author":"PP Rose","year":"2000","journal-title":"Bioinformatics"},{"issue":"4","key":"pcbi.1010624.ref076","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: improvements in performance and usability","volume":"30","author":"K Katoh","year":"2013","journal-title":"Mol Biol Evol"},{"issue":"4","key":"pcbi.1010624.ref077","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/bioinformatics\/btq706","article-title":"phangorn: phylogenetic analysis in R.","volume":"27","author":"KP Schliep","year":"2011","journal-title":"Bioinformatics."},{"issue":"5","key":"pcbi.1010624.ref078","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","article-title":"IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era.","volume":"37","author":"BQ Minh","year":"2020","journal-title":"Mol Biol Evol"},{"issue":"6","key":"pcbi.1010624.ref079","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nmeth.4285","article-title":"ModelFinder: fast model selection for accurate phylogenetic estimates.","volume":"14","author":"S Kalyaanamoorthy","year":"2017","journal-title":"Nat Methods."},{"issue":"W1","key":"pcbi.1010624.ref080","doi-asserted-by":"crossref","first-page":"W24","DOI":"10.1093\/nar\/gkx346","article-title":"BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes","volume":"45","author":"MC Jespersen","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"pcbi.1010624.ref081","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all.","volume":"19","author":"M Mirdita","year":"2022","journal-title":"Nat Methods."},{"issue":"16","key":"pcbi.1010624.ref082","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/bioinformatics\/bty1057","article-title":"MMseqs2 desktop and local web server app for fast, interactive sequence searches","volume":"35","author":"M Mirdita","year":"2019","journal-title":"Bioinformatics"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T17:38:38Z","timestamp":1667237918000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010624"}},"subtitle":[],"editor":[{"given":"Rob J.","family":"De Boer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":82,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1010624","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}